# US 12,006,551 B1 · MiRNA marker for diagnosis and/or treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,551 B1
- Document ID: US12006551B1
- Status: Granted
- Kind: B1
- Application number: 17/865,475
- Filed: 2022-07-15
- Granted: 2024-06-11
- Earliest claimed: 2019-11-06
- Assignees: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking University
- Applicants: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College
- Inventors: Rui Liu; Zhuorong Li; Li Zeng; Ting Sun; Mimin Liu; Junxia Zhang
- Web page: https://patentgrep.com/patent/US12006551B1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The miRNA23 cluster is used in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3β-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.

## Claims

### Claim 1

A method for treating a mouse with Alzheimer's disease (AD), comprising injecting adeno-associated virus (AAV) carrying hsa-miR-23b into the mouse with Alzheimer's disease (AD), wherein the hsa-miR-23b consists of SEQ ID NO: 1.